What are Brukinsa and Jaypirca, and what do they treat?
Brukinsa (zanubrutinib) and Jaypirca (pirtobrutinib) are both oral BTK inhibitors used for certain B-cell blood cancers. Brukinsa is a BTK inhibitor used in treatment settings that include chronic lymphocytic leukemia (CLL) and related disorders, while Jaypirca is also a BTK inhibitor used in CLL and related cancers, including in patients who have already had BTK inhibitor therapy (based on available labeling and clinical use). [1][2]
How are they different: “type” of BTK inhibitor (reversible vs other binding)
A key practical difference is that Jaypirca (pirtobrutinib) is designed as a reversible (non-covalent) BTK inhibitor, while Brukinsa (zanubrutinib) is a covalent BTK inhibitor. That distinction matters most in patients who have previously been exposed to covalent BTK inhibitors and may have developed resistance. [1][2]
Which one is used after prior BTK inhibitor treatment?
Jaypirca is commonly used when cancers have progressed after earlier BTK inhibitor therapy, because its non-covalent/reversible mechanism can still inhibit BTK even when resistance occurs with covalent inhibitors. Brukinsa is also used across BTK inhibitor treatment pathways, including later lines in appropriate patients, but its role after prior BTK exposure is more tied to the covalent BTK inhibitor approach. [1][2]
How do side effects typically compare?
Both drugs are BTK inhibitors, so they share class effects such as bruising/bleeding risk and infections, and they can also raise concerns like low blood counts (depending on the regimen and patient). The biggest way they differ is less about completely different toxicities and more about how patients tolerate them and how well they control disease after prior therapy. Specific side-by-side adverse-event rates depend on the exact study population and line of therapy. [1][2]
What patient factors influence the choice between them?
Clinicians generally consider:
- Whether the patient has already had a BTK inhibitor before, and which one.
- Disease subtype and treatment line (first line vs later lines).
- Comorbidities affecting bleeding risk, infections, and blood counts.
- Drug-drug interaction potential and overall tolerability goals.
Because Jaypirca’s mechanism can matter after prior BTK inhibitor resistance, it often becomes a key option in that setting. [1][2]
Are they interchangeable?
They’re not interchangeable in practice because they differ in mechanism and clinical positioning (including use after prior BTK inhibitor exposure). The choice is usually driven by prior treatments and disease status rather than a simple “either one works the same way” comparison. [1][2]
Sources
- https://www.accessdata.fda.gov/drugsatfda_docs/label/ (Brukinsa prescribing information page)
- https://www.accessdata.fda.gov/drugsatfda_docs/label/ (Jaypirca prescribing information page)
If you share what cancer type and prior treatments you mean (for example, “CLL after ibrutinib/acalabrutinib” or “mantle cell lymphoma”), I can compare the most relevant uses and practical differences for that exact scenario.